Efgartigimod alpha, by blocking FcRn, reduces the recycling of pathogenic autoantibodies, leading to clinical improvement in patients with autoimmune diseases such as MG and stiff-person syndrome (SPS) [10]. The gene discussed is FCGRT; the disease is myasthenia gravis.